Cost-Effectiveness of Enfuvirtide for Treatment-Experienced Patients with HIV in Italy
- 1 April 2005
- journal article
- Published by Taylor & Francis Ltd in HIV Research & Clinical Practice
- Vol. 6 (2), 92-102
- https://doi.org/10.1310/rejm-tafw-0a7t-97ua
Abstract
Enfuvirtide (ENF) plus an optimized background (OB) antiretroviral regimen delays virological failure (VF), reduces HIV-1 viral load, and increases CD4 count compared with OB only in pretreated patients. To forecast long-term outcomes, costs, and cost-effectiveness of ENF+OB vs. OB in the Italian health care system. A Markov model was developed and clinical trial results on viral suppression and CD4 count were linked with data from HAART-era studies of the risk of AIDS-defining events (ADEs) and death. Resource data were obtained from Italian sources on direct medical costs. Cost-effectiveness was computed as the incremental cost per quality-adjusted life year (QALY) saved. Patients receiving ENF+OB were projected to experience a mean time to virological failure of 1.0 years vs. 0.5 years for OB and mean time to immunological failure of 3.1 years vs. 1.3 years for OB. Life expectancy and QALYs were greater for ENF+OB than OB by 1.8 and 1.5 years, respectively. Total lifetime medical cost was euro 126,487 for ENF+OB and euro 84,416 for OB, a difference of euro 42,071 due to the cost of ENF itself (euro 18,400) and the medical costs associated with additional life expectancy (euro 23,671). The incremental cost-effectiveness of ENF+OB was euro 23,721 per life year (euro 28,669 per QALY). ENF+OB is predicted to increase life expectancy at a cost per life year that is comparable to many well-accepted therapies in Europe.Keywords
This publication has 35 references indexed in Scilit:
- Patient Acceptance of Self-Injected Enfuvirtide at 8 and 24 WeeksHIV Research & Clinical Practice, 2003
- Antiretroviral-Drug Resistance among Patients Recently Infected with HIVNew England Journal of Medicine, 2002
- Long-Term Treatment with Subcutaneous T-20, a Fusion Inhibitor, in HIV-Infected Patients: Patient Satisfaction and Impact on Activities of Daily LivingAIDS Patient Care and STDs, 2002
- Decreased morbidity and use of hospital services in English HIV-infected individuals with increased uptake of anti-retroviral therapy 1996-1997AIDS, 1999
- HIV-1–specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapyJCI Insight, 1999
- HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatmentAIDS, 1999
- Modeling the Long-Term Outcomes and Costs of HIV Antiretroviral Therapy Using HIV RNA Levels: Application to a Clinical TrialAIDS Research and Human Retroviruses, 1999
- Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in PlasmaScience, 1996
- Markov models of natural historyJournal of Clinical Epidemiology, 1988
- The Markov Process in Medical PrognosisMedical Decision Making, 1983